Skip to content
OpenCapital
Get started

Johnson & Johnson JNJ EPS (Diluted)

EPS (Diluted) at other companies

Abbott logo
AbbottABT
$0.61-19.7%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.31+9.2%
Tenet Healthcare logo
Tenet HealthcareTHC
$8.01+87.6%
Pfizer logo
PfizerPFE
$0.47-9.6%
Procter & Gamble logo
Procter & GamblePG
$1.63+5.8%
Merck & Co. logo
Merck & Co.MRK
-$1.72-186%

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$589.48B+63.6%
Enterprise value$622.78B+66.4%
P/E28×+11.5×
P/S6.1×+2.1×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's EPS (diluted)?
Johnson & Johnson (JNJ) reported EPS (diluted) of $2.14 in Q1 2026.
How has Johnson & Johnson's EPS (diluted) changed year-over-year?
Johnson & Johnson's EPS (diluted) decreased by 52.9% year-over-year, from $4.54 to $2.14.
What is the long-term trend for Johnson & Johnson's EPS (diluted)?
Over 4 years (2021 to 2025), Johnson & Johnson's EPS (diluted) has grown at a 9.0% compound annual growth rate (CAGR), from $7.81 to $11.04.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.